aibio
Company Updates ·
Aethlon stockholders approve 200,000,000 authorized common shares
At an October 1, 2026 virtual annual meeting, stockholders also approved 100,000 more shares for the equity plan and 20,000,000 authorized preferred shares.
AEMD AETHLON MEDICAL INC
AETHLON MEDICAL INC (AEMD) news AEMD reverse split and offering news
Latest AETHLON MEDICAL INC news
- Mergers
Aethlon to merge with North Immunology in an all-stock deal
The deal comes with an oversubscribed $180 million private placement. Aethlon holders are expected to own about 4.75% of the combined company at closing, expected in the first quarter of 2027.
- Company Updates
Aethlon reports first-quarter fiscal 2027 results and third-cohort dosing
The company reported cash of approximately $4.9 million at June 30, 2026, after raising about $4.0 million in gross proceeds after quarter-end, and operating expenses down 11.9%.
- Listings
Aethlon effects 1-for-5 reverse stock split effective July 31
The split takes effect at 10:00 a.m. Eastern Time on July 31, 2026, and shares are expected to trade split-adjusted on August 4, 2026 under AEMD.
- Financings
Aethlon prices $4.0 million follow-on offering at $0.7101 per share
Maxim Group LLC is sole placement agent for 5,633,009 shares or pre-funded warrants, each sold with a warrant for the same number of shares.
- Company Updates
Aethlon Medical reports fiscal 2026 results and enters third cohort
Aethlon Medical reported a net loss of $7.2 million for the fiscal year ended March 31, 2026, and said its Australian oncology study has entered its third and final dosing cohort.
What AETHLON MEDICAL INC does
Aethlon Medical, Inc. is a medical therapeutic company developing the Hemopurifier, a clinical-stage investigational immunotherapeutic device. It uses a proprietary lectin-based technology to bind and remove enveloped viruses and extracellular vesicles (EVs) from biological fluids. The company targets oncology, life-threatening infectious diseases, organ transplantation and other disease states in which EVs contribute to progression. The FDA has granted the Hemopurifier Breakthrough Device designation for advanced or metastatic cancer unresponsive to or intolerant of standard-of-care therapy, and for life-threatening viruses not addressed with approved therapies. The company is conducting a safety, feasibility and dose-finding trial in Australia in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy, designed to enroll approximately 9 to 18 participants. The company completed the second cohort in March 2026, and the Data Safety Monitoring Board approved advancement to a third cohort. The device has been evaluated in human studies involving 173 treatment sessions in 44 patients with either viral infections or cancer.
| Product or program | What it is | Stage |
|---|---|---|
| Hemopurifier (HP) | Lectin-based device that removes enveloped viruses and extracellular vesicles from fluids | clinical-stage investigational |
AETHLON MEDICAL INC annual financials
| Line | FY ended Mar 31, 2026 | FY ended Mar 31, 2025 |
|---|---|---|
| Research and development | $1.9 million | $2.2 million |
| Net income (loss) | -$7.2 million | -$13.4 million |
| Cash from operations | -$7.0 million | -$7.6 million |
| Cash and equivalents | $5.0 million | $5.5 million |
Questions about AETHLON MEDICAL INC
Did AETHLON MEDICAL INC do a reverse stock split?
Our latest story on this, dated Jul 31, 2026: "Aethlon effects 1-for-5 reverse stock split effective July 31". The story links the filing or release it is based on. Read the story.
Has AETHLON MEDICAL INC raised money recently?
Our latest story on this, dated Sep 17, 2026: "Aethlon to merge with North Immunology in an all-stock deal". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of AETHLON MEDICAL INC?
AETHLON MEDICAL INC trades under the ticker AEMD on NASDAQ.
Where is AETHLON MEDICAL INC listed?
AETHLON MEDICAL INC is listed on NASDAQ.
Which country or territory is AETHLON MEDICAL INC listed under?
Our directory records AETHLON MEDICAL INC under United States.
Does aibio.space cover AETHLON MEDICAL INC?
aibio.space lists AETHLON MEDICAL INC among 2,820 public biotech companies and publishes its news here as stories appear.
What does AETHLON MEDICAL INC develop?
Aethlon Medical, Inc. is a medical therapeutic company developing the Hemopurifier, a clinical-stage investigational immunotherapeutic device. It uses a proprietary lectin-based technology to bind and remove enveloped viruses and extracellular vesicles (EVs) from biological fluids.
What is Hemopurifier (HP) from AETHLON MEDICAL INC?
Hemopurifier (HP): Lectin-based device that removes enveloped viruses and extracellular vesicles from fluids Stage: clinical-stage investigational.
Is AETHLON MEDICAL INC profitable?
AETHLON MEDICAL INC reported a net loss of $7.2 million for the fiscal year ended Mar 31, 2026, and used $7.0 million of cash in operations, per its annual report to the SEC.
How much does AETHLON MEDICAL INC spend on research and development?
$1.9 million in the fiscal year ended Mar 31, 2026, per its annual report.
How much cash does AETHLON MEDICAL INC have?
$4.9 million in cash at Jun 30, 2026, per its 10-Q.
What is the latest AETHLON MEDICAL INC (AEMD) stock news?
Our latest story on AETHLON MEDICAL INC, dated Oct 1, 2026: "Aethlon stockholders approve 200,000,000 authorized common shares". At an October 1, 2026 virtual annual meeting, stockholders also approved 100,000 more shares for the equity plan and 20,000,000 authorized preferred shares. Source.
How long will AETHLON MEDICAL INC's cash last?
From our story of Aug 13, 2026: Based on current plans, the company believes its cash resources are sufficient to fund operations for at least the next 12 months. Source.
Is AETHLON MEDICAL INC being acquired or merging?
Our latest merger story, dated Sep 17, 2026: "Aethlon to merge with North Immunology in an all-stock deal". The deal comes with an oversubscribed $180 million private placement. Aethlon holders are expected to own about 4.75% of the combined company at closing, expected in the first quarter of 2027. Source.
How can I follow AETHLON MEDICAL INC (AEMD) news?
Press Follow on this page to add AETHLON MEDICAL INC to your Following list, or subscribe to the aibio.space newsletter. We have published 6 stories naming AETHLON MEDICAL INC so far, in Company Updates, Financings, Listings, Mergers.
Investor discussion: AETHLON MEDICAL INC
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). Source
- Mergers
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,5.01,7.01,9.01). Source
- Listings
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). Source
- Financings
Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). Source
- Financings
Filed a registration statement for a share offering. SEC Form S-1. Source
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Stock chart
Listing details
- Company
- AETHLON MEDICAL INC
- Ticker
- AEMD
- Listing
- NASDAQ
- Country or territory
- United States
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction